Showing 5531-5540 of 8845 results for "".
- Possible Eczema Breakthrough? S. aureus May Promote Skin Inflammation via IL-36-Mediated T Cell Responseshttps://practicaldermatology.com/news/possible-eczema-breakthrough-s-aureus-may-promotes-skin-inflammation-via-il-36-mediated-t-cell-responses/2457978/Toxin-producing bacteria on the surface of our skin may induce a protein that causes our own cells to react and cause inflammation, according to research published online in Cell Host & Microbe. <
- Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Executionhttps://practicaldermatology.com/news/novan-plans-to-complete-development-of-sb204-acne-candidate-via-third-party-funding-and-execution/2457981/Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Dr
- Save the Dates: eRelevance Launches National Marketing Education Tour for Aesthetic Healthcare Practiceshttps://practicaldermatology.com/news/erelevance-launches-national-marketing-education-tour-for-aesthetic-healthcare-practices/2457983/eRelevance Corporation announced the expansion of its popular marketing education workshops to more cities nationwide. The workshops help aesthetic healthcare providers understand the significant opportunity in marketing to their existing patient
- Gut Microbiome May Affect How Metastatic Melanoma Responds to Immunotherapyhttps://practicaldermatology.com/news/gut-microbiome-may-affect-how-metastatic-melanoma-responds-to-immunotherapy/2457986/The gut microbiome can influence how metastatic melanoma responds to immunotherapy, researchers from The University of Texas MD Anderson Cancer Center report in the journal
- FDA Accepts Ortho Dermatologic's NDA for Novel Plaque Psoriasis Treatment, IDP-118https://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-nda-for-novel-plaque-psoriasis-treatment-idp-118/2457988/The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date i
- Use of a New Holographic Hand Piece May Improve Picosecond Laser Treatment of Acne Scarshttps://practicaldermatology.com/news/study-adding-a-holographic-beam-splitter-to-picosecond-laser-improves-acne-scars/2457993/Incorporating a new holographic beam splitter in a picosecond laser may help improve the appearance of acne scars, according to a study published in Lasers in Surgery and Medicine (LSM). The paper was selecte
- Chris Greta Appointed Chief Creative Officer at eRelevancehttps://practicaldermatology.com/news/chris-greta-appointed-chief-creative-officer-at-erelevance/2457996/Chris Greta has been appointed as the first chief creative officer for
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by
- FDA Approves Janssen's Golimumab for PsA, AShttps://practicaldermatology.com/news/fda-approved-jansens-golimumab-for-psa-as/2457998/The FDA approved Janssen’s SIMPONI ARIA (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only fully-human anti-tumor necrosis factor (TNF
- Dr. Daniel Siegel Joins DermTech's Advisory Boardhttps://practicaldermatology.com/news/dr-daniel-siegel-joins-dermtechs-advisory-board/2458000/DermTech, Inc., appointed Daniel M. Siegel, MD, to its Scientific Advisory Board. Dr. Siegel is a Clinical Professor of Dermatology and former Director of the Procedural Dermatology Fellowship at SUNY Downstate. He has served as a president of the American Academy of Dermatology (AAD) and is a pa